Lyell Immunopharma (LYEL) Share-based Compensation (2020 - 2025)

Lyell Immunopharma (LYEL) has 6 years of Share-based Compensation data on file, last reported at $25.6 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation rose 216.33% year-over-year to $25.6 million; the trailing twelve-month figure through Mar 2026 stood at $35.8 million (up 19.3% YoY), and the FY2025 full-year result was $41.8 million, up 26.2% from the prior year.
• Share-based Compensation rose to $25.6 million in Q4 2025, from $5.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $116.0 million in Q2 2021 to a low of -$22.0 million in Q2 2022.
• A 5-year average of $18.2 million and a median of $8.5 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 118.99% in 2022 and soared 10391.01% in 2023, its largest moves.
• Tracing LYEL's Share-based Compensation over 5 years: stood at $13.0 million in 2021, then surged by 525.34% to $81.6 million in 2022, then tumbled by 89.62% to $8.5 million in 2023, then decreased by 4.49% to $8.1 million in 2024, then soared by 216.33% to $25.6 million in 2025.
• Business Quant data shows LYEL's Share-based Compensation at $25.6 million in Q4 2025, $5.2 million in Q3 2025, and $5.0 million in Q2 2025.